Corvus Pharmaceuticals (CRVS) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corvus Pharmaceuticals is the larger company by market cap ($858.9 million vs $756.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | OBX |
|---|---|---|
| Share price | $10.21 | $12.24 |
| Market cap | $858.87M | $756.10M |
| 1-day change | -1.92% | -7.27% |
| YTD return | +32.60% | — |
| 1-year return | +45.86% | — |
| 5-year return | +106.26% | — |
| EPS (TTM) | $-0.62 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $49.97 |
| 52-week low | $6.39 | $12.07 |
| Distance from 52-week high | -62.12% | -75.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +224.58% | +218.63% |
| Average volume | 986.04K | 367.35K |
| Shares outstanding | 84.12M | 61.77M |
| Employees | 37 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
CRVS vs OBX FAQ
Which is bigger, Corvus Pharmaceuticals or Obsidian Therapeutics?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $858.87M compared with $756.10M for Obsidian Therapeutics (OBX).
Are Corvus Pharmaceuticals and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.